Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25537483 | 0.85 | KMT2A (0.73) | KMT2AMEN1LMNAALDH1A1JAK1 | |
| SCHEMBL12394322 | 0.82 | SIGMAR1 (0.55) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL10690328 | 0.82 | LMNA (0.80) | LMNAALDH1A1KDM4EHRH3SIGMAR1 | |
| SCHEMBL1427500 | 0.81 | KMT2A (0.69) | KMT2AMEN1LMNAALDH1A1LTA4H | |
| SCHEMBL10196835 | 0.81 | KMT2A (1.00) | KMT2AMEN1LMNAALDH1A1LTA4H | |
| SCHEMBL2029947 | 0.81 | KMT2A (0.69) | KMT2AMEN1LMNAALDH1A1JAK1 | |
| SCHEMBL13982034 | 0.81 | KMT2A (0.74) | KMT2AMEN1LMNAALDH1A1JAK1 | |
| SCHEMBL3621186 | 0.81 | LMNA (0.62) | KMT2AMEN1LMNAALDH1A1JAK1 | |
| SCHEMBL3319068 | 0.81 | KMT2A (0.68) | KMT2AMEN1LMNALTA4HCYP1A2 | |
| SCHEMBL13594973 | 0.81 | MEN1 (0.68) | KMT2AMEN1LMNAALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | claimed |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| CN-114181199-B | 2, 4-disubstituted pyrimidine derivative, preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| CN-114181199-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1548065-A1 | FLAME-RETARDANT POLYCARBONATE RESIN COMPOSITION | Sumitomo Dow Limited (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | KMT2A 2908/4885MEN1 4292/4885LMNA 2159/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | KMT2A 3530/4885MEN1 1288/4885LMNA 1884/4885 |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | KMT2A 901/4885MEN1 792/4885LMNA 3211/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | KMT2A 1370/4885MEN1 4629/4885LMNA 4665/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | KMT2A 3519/4885MEN1 4385/4885LMNA 2464/4885 |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | JAK2, JAK1, JAK3 | KMT2A 619/4885MEN1 4068/4885LMNA 4860/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | KMT2A 3519/4885MEN1 4385/4885LMNA 2464/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | KMT2A 835/4885MEN1 4037/4885LMNA 4718/4885 |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | KMT2A 4529/4885MEN1 4229/4885LMNA 1282/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | KMT2A 750/4885MEN1 3345/4885LMNA 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.